-
-
-
-
-
-
-
Jefferies Assumes Fate Therapeutics (FATE) at Buy
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Tops Q3 EPS by 3c
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Tops Q2 EPS by 5c
-
-
-
-
-
-
-
Fate Therapeutics (FATE) PT Lowered to $4 at Baird
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
-
-
-
-
-
-
-
Fate Therapeutics (FATE) PT Lowered to $5 at BMO Capital
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Tops Q2 EPS by 13c
-
456,987 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

